(0.25%) 5 112.53 points
(0.21%) 38 321 points
(0.26%) 15 969 points
(-1.45%) $82.63
(3.90%) $1.998
(0.03%) $2 347.80
(0.04%) $27.55
(3.57%) $955.00
(-0.19%) $0.933
(-0.35%) $10.99
(-0.47%) $0.797
(1.71%) $93.45
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 5.29%
@ $374.79
发出时间: 26 Apr 2024 @ 22:35
回报率: -0.08%
上一信号: Apr 26 - 03:51
上一信号:
回报率: 1.05 %
Live Chart Being Loaded With Signals
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France...
Stats | |
---|---|
今日成交量 | 47 006.00 |
平均成交量 | 288 162 |
市值 | 22.26B |
EPS | $0 ( 2024-02-29 ) |
下一个收益日期 | ( $-0.710 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -72.86 |
ATR14 | $6.88 (1.84%) |
音量 相关性
argenx SE 相关性 - 货币/商品
argenx SE 财务报表
Annual | 2023 |
营收: | $1.23B |
毛利润: | $1.11B (90.39 %) |
EPS: | $-5.16 |
FY | 2023 |
营收: | $1.23B |
毛利润: | $1.11B (90.39 %) |
EPS: | $-5.16 |
FY | 2022 |
营收: | $410.75M |
毛利润: | $381.32M (92.83 %) |
EPS: | $-13.05 |
FY | 2021 |
营收: | $497.28M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-7.99 |
Financial Reports:
No articles found.
argenx SE
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。